Arvinas (ARVN)
(Delayed Data from NSDQ)
$26.16 USD
+0.12 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $26.15 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.16 USD
+0.12 (0.46%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $26.15 -0.01 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Zacks News
New Strong Sell Stocks for November 16th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -12.07% and 0.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Arvinas, Inc. (ARVN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why
by Zacks Equity Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Arvinas (ARVN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 5.08% and 20.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ARVN) Outperforming Other Medical Stocks This Year?
Why You Shouldn't Bet Against Arvinas (ARVN) Stock
by Zacks Equity Research
Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.66% and 2.69%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for Emerson (EMR) in Q1 Earnings?
by Zacks Equity Research
Emerson's (EMR) fiscal Q1 earnings are likely to have gained from steady demand in process and hybrid end markets. Weak global discrete manufacturing market might have been a concern.
Will Arvinas Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Arvinas.
Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will Arvinas Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Arvinas.